About
Lasting Effect develops pharmaceutical therapeutics based on a proprietary buccal extended-release drug delivery system. The company’s technology utilizes adhesive tablets designed to attach to the oral mucosa, enabling the continuous administration of active ingredients either topically or systemically while bypassing the digestive tract. This approach effectively addresses challenges such as swallowing difficulties (dysphagia) and administration compliance often associated with traditional oral or invasive delivery methods. Key applications of the platform include saliva-stimulating treatments for dry mouth (xerostomia) and anti-bacterial formulations for gingivitis. Additionally, the company offers a non-invasive solution for late-stage Parkinson’s disease, providing prolonged dopamine secretion as an alternative to continuous infusion pumps. By ensuring sustained drug release, the solution maintains consistent therapeutic levels and enhances patient care for chronic conditions.
Funding history · 1 round · $1.9M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Lasting Effect Consumer Pharma's primary focus?
- Lasting Effect Consumer Pharma develops pharmaceutical therapeutics using a proprietary buccal extended-release drug delivery system, which involves adhesive tablets for continuous administration of active ingredients.
- When was Lasting Effect Consumer Pharma founded?
- Lasting Effect Consumer Pharma was founded in March 2020.
- What is the current employee count for Lasting Effect Consumer Pharma?
- Lasting Effect Consumer Pharma currently has 7 employees.
- What was Lasting Effect Consumer Pharma's total funding raised as of the latest data?
- Lasting Effect Consumer Pharma has raised a total of $1,850,000 USD.
- When did Lasting Effect Consumer Pharma complete its Pre-Seed funding round and who were some of the investors?
- In January 2023, Lasting Effect Consumer Pharma completed a Pre-Seed funding round of $1,000,000 USD, with investors including MaccabiDent, OurCrowd, and Padagis.
- Has Lasting Effect Consumer Pharma received any grants?
- Yes, in January 2023, Lasting Effect Consumer Pharma received an $850,000 USD grant from the IIA.
- What are some key applications of Lasting Effect Consumer Pharma's buccal drug delivery platform?
- Key applications include saliva-stimulating treatments for dry mouth (xerostomia), anti-bacterial formulations for gingivitis, and a non-invasive solution for late-stage Parkinson’s disease.
- Who are the founders of Lasting Effect Consumer Pharma?
- The founders of Lasting Effect Consumer Pharma are David Tavor, Igal Pikovsky, and Eli Heldman.
- What is the current product stage for Lasting Effect Consumer Pharma?
- Lasting Effect Consumer Pharma's products are currently in the clinical trial stage.